- Home
- PHVS
PHVS
Pharvaris N.V.
as 11-22-2024 4:00pm EST
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .
| Founded: | 2015 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.0B | IPO Year: | 2021 |
| Target Price: | $35.67 | AVG Volume (30 days): | 67.6K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.37 - $33.00 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Pharvaris N.V. News
PHVS Breaking Stock News: Dive into PHVS Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
GlobeNewswire
12 days ago
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
GlobeNewswire
a month ago
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
GlobeNewswire
a month ago
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
GlobeNewswire
a month ago
Pharvaris to Host Virtual Investor Event on October 23, 2024
GlobeNewswire
2 months ago
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
MT Newswires
2 months ago
JonesTrading Initiates Coverage on Pharvaris With Buy Rating, $46 Price Target
Simply Wall St.
2 months ago
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
Compare PHVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHVS Pharvaris N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.